This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I09 (Other rheumatic heart diseases) | Special Copayment Reduction: V192 (Special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Rheumatic myocarditis (I09.0), rheumatic endocarditis (I09.1), chronic rheumatic pericarditis (I09.2), rheumatic heart disease, not elsewhere classified (I09.9), rheumatic pancarditis |
| C. Adult onset | Rheumatic myocarditis mainly presents together with acute rheumatic fever and also appears in adults during the first attack. Chronic rheumatic pericarditis may progress to constrictive pericarditis over decades after repeated pericardial inflammation. |
| 1. History | 19th-century studies of rheumatic cardiac pathology by Bouillaud and Aschoff established the descriptions of myocarditis and pericarditis. Introduction of corticosteroids and antibiotics in the 20th century transformed treatment. Echocardiography made it possible to detect asymptomatic lesions. |
| 2. Causes | Autoimmune response after group A streptococcal pharyngitis. Cross-reactive antibodies and T-cell infiltration against the myocardium, pericardium, and endocardium. Components of pancarditis in acute rheumatic fever. |
| 3. Genetics | The HLA-associated immunogenetics of rheumatic fever apply equally. TNF-α and IL-1 gene polymorphisms associated with the severity of myocarditis. Genetic studies on a predisposition to pericarditis are limited. |
| 4. General epidemiology | Cardiac involvement in 50–80% of acute rheumatic fever. Pericarditis in 5–10%; myocarditis is the main cause of death from rheumatic fever. Concentrated in low- and middle-income countries. In developed countries, myocarditis and pericarditis of nonrheumatic causes are more common. |
| 5. Pathophysiology | Autoimmune response through molecular mimicry: T-cell- and antibody-mediated inflammation against cardiac myosin, valvular endothelium, and pericardium. The Aschoff body is the characteristic histologic lesion of myocarditis. |
| 6. Symptoms | Myocarditis: palpitations, dyspnea, fatigue, heart failure symptoms. Pericarditis: precordial chest pain (relieved by leaning forward), friction rub. Constrictive pericarditis: ascites, edema, exercise intolerance. |
| 7. Signs | Myocarditis: tachycardia, cardiomegaly, gallop rhythm, new heart murmur. Pericarditis: pericardial friction rub, positional chest pain. Constrictive: Kussmaul sign, pericardial knock, ascites. |
| 8. Screening | When acute rheumatic fever is diagnosed, confirming myocardial and pericardial involvement by echocardiography is essential. Cardiac MRI is superior for assessing the extent of myocarditis and pericardial thickness. CT and MRI are recommended for screening for pericarditis complications (constrictive pericarditis). |
| 9. Diagnosis | Echocardiography (left ventricular function, pericardial effusion, pericardial thickness), cardiac MRI (myocardial edema and fibrosis, pericardial thickening), electrocardiography (ST-segment abnormalities, PR prolongation), cardiac enzymes (CK-MB, troponin). Pericardial biopsy is rarely performed. |
| 10. Treatment | Myocarditis: corticosteroids (severe), heart failure treatment (ACE inhibitors, diuretics, beta-blockers). Pericarditis: aspirin, NSAIDs, colchicine. Constrictive pericarditis: surgical pericardiectomy. |
| 11. Prognosis | Myocarditis: risk of death in the acute phase. In survivors, cardiac function recovers in many. Progresses to dilated cardiomyopathy in some. Constrictive pericarditis: symptomatic improvement in 70–85% after pericardiectomy. |
| 12. Prevention | Secondary prevention (benzathine penicillin G) to prevent rheumatic recurrence. Colchicine for prevention of pericarditis recurrence. Follow-up echocardiography is essential when left ventricular function is reduced after myocarditis. |
| 13. References | Rheumatic Disease of the Cardiac Muscle (PMC, 2016) … and 9 other papers |
Other rheumatic heart diseases (I09) encompass rheumatic involvement of cardiac structures other than the valves—the myocardium, endocardium, and pericardium. Among these, the pathologic understanding of rheumatic myocarditis began with the groundbreaking 1904 work of the German pathologist Ludwig Aschoff. Aschoff described the 'Aschoff body', the characteristic histologic lesion of rheumatic myocarditis. This lesion is a granulomatous reaction forming a central area of necrosis around small vessels in the myocardium, a structure in which the necrosis is surrounded by Aschoff cells (activated macrophages, also called 'Anitschkow cells' or 'owl-eye cells') and lymphocytes. This histologic finding is still used today as the pathologic criterion for confirming rheumatic myocarditis.
In the early 19th century, Jean-Baptiste Bouillaud of France systematically studied the association between rheumatic fever and cardiac involvement and contributed to establishing the concept of pancarditis, in which acute rheumatic fever involves the endocardium, myocardium, and pericardium. After the 1950s, the clinical introduction of corticosteroids made acute-phase treatment of severe myocarditis possible, but evidence that steroids prevent the progression of chronic rheumatic heart disease has not yet been established. With the spread of echocardiography, the concept of 'subclinical carditis', detected only by echocardiography without a clinical heart murmur, was established, and this was reflected in the 2015 revised Jones criteria, making echocardiographic findings a major diagnostic criterion for carditis as well.
The cause of other rheumatic heart diseases is the autoimmune response after group A beta-hemolytic streptococcal (GAS) pharyngitis, the same as for I01 (rheumatic fever with heart involvement). Through molecular mimicry, cross-reactive antibodies and T cells formed against epitopes of the streptococcal M protein attack cardiac tissue. In the myocardium, the S2 fragment of cardiac myosin, and vimentin, laminin, etc. of valvular endothelial cells act as autoantigens. Pericardial involvement occurs when cellular and humoral immune responses to cardiac self-antigens extend to the pericardium, causing fibrinous or effusive pericarditis.
Among the other rheumatic heart diseases under I09, rheumatic endocarditis (I09.1) is rheumatic endocarditis involving an unspecified valve and includes valvular lesions that are not clearly classified. Chronic rheumatic pericarditis (I09.2) is a condition in which pericardial fibrosis progresses after acute rheumatic pericarditis, thickening the pericardium and causing adhesion of the tissues around the heart. In severe cases it progresses to constrictive pericarditis, causing impaired ventricular relaxation and reduced cardiac output.
The genetic basis of other rheumatic heart diseases is the same as the immunogenetic susceptibility to rheumatic fever in general. HLA class II genes (HLA-DR7, HLA-DRB1-related alleles) partly determine the risk of rheumatic fever and cardiac involvement. Studies have reported that TNF-α promoter polymorphisms (-308G/A, etc.) and IL-1β gene polymorphisms are involved in the severity of myocarditis.
The important role of MHC (major histocompatibility complex) genes in autoimmune myocarditis in general has also been confirmed in animal models. Genetic factors involved in the development of rheumatic pericarditis and its progression to constrictive pericarditis have not yet been sufficiently studied. Familial clustering is observed in rheumatic fever in general, but data on a specific familial tendency toward myocarditis or pericarditis are limited. Clinically, genetic testing is currently not routinely recommended for other rheumatic heart diseases.
Some form of cardiac involvement occurs in 50–80% of patients with acute rheumatic fever. Pericarditis is clinically apparent in about 5–10% of acute rheumatic fever and is found at a higher frequency when detected by echocardiography. Rheumatic myocarditis is the main cause of death from acute rheumatic fever, and death from heart failure due to severe pancarditis was not uncommon in the past.
As the incidence of rheumatic fever has declined in developed countries, the occurrence of rheumatic myocarditis and pericarditis has also decreased, but they remain an important medical burden in low- and middle-income countries. In developed East Asian countries including Korea, myocarditis and pericarditis due to causes other than rheumatic fever (viral, autoimmune) are much more common, so a rheumatic cause must be distinguished through the clinical context (history of rheumatic fever, evidence of streptococcal infection).
The key pathogenetic mechanism of rheumatic myocarditis is a T-cell- and antibody-mediated autoimmune response through molecular mimicry. Because epitopes of the streptococcal M protein are structurally similar to cardiac myosin (myosin heavy chain, alpha-MHC), the T-cell response to the M protein is directed against the myocardium. Autoreactive CD4+ T cells infiltrate the myocardium, secrete cytokines (IFN-γ, IL-17, TNF-α, etc.), induce direct cytotoxicity, and, together with complement activation, damage cardiomyocytes.
Aschoff bodies are located around small vessels in the myocardium and consist of central fibrinoid necrosis, Anitschkow cells (modified macrophages with balloon-shaped nuclei), lymphocytes, and plasma cells. As these lesions heal, fibrotic scars form in the myocardium. In pericarditis, fibrinous exudate accumulates between the visceral and parietal pericardium, giving a 'bread and butter pericarditis' appearance, and when this progresses to pericardial thickening and adhesions during healing, it becomes a cause of constrictive pericarditis.
The symptoms of rheumatic myocarditis are proportional to the degree of myocardial dysfunction. In mild myocarditis, patients may be asymptomatic or have only palpitations and mild exercise intolerance. In moderate or more severe cases, heart failure symptoms such as dyspnea, fatigue, edema, and orthopnea appear, and in severe cases it can lead to acute heart failure and cardiogenic shock. Rheumatic myocarditis is the most common cause of death due to acute rheumatic fever.
Chest pain is the most characteristic symptom of rheumatic pericarditis. The chest pain is sharp and stabbing in the precordium or left chest, worsens on inspiration (pleuritic chest pain), and is relieved by leaning forward. Fever, fatigue, and epigastric discomfort (with pericardial effusion) also accompany it. With a large pericardial effusion, dyspnea becomes severe, and when cardiac tamponade develops, Beck's triad of tamponade—hypotension, tachycardia, and jugular venous distension—appears. In chronic constrictive pericarditis, ascites, lower limb edema, and exercise intolerance due to reduced cardiac output are the main symptoms.
Physical signs of rheumatic myocarditis include resting tachycardia (heart rate over 100), cardiomegaly, a third heart sound (S3, gallop rhythm), a new heart murmur, and hypotension. A new mitral regurgitation murmur is caused by mitral annular dilation due to myocardial dysfunction or papillary muscle dysfunction. When left heart failure has progressed, crackles at both lung bases and findings of pulmonary edema appear.
The typical sign of rheumatic pericarditis is a pericardial friction rub. This finding is difficult to hear and may be heard only intermittently; it is heard in both inspiration and expiration and better in the leaning-forward position. The rub consists of three components (atrial systole, ventricular systole, early diastole), but not all may be heard. With a large pericardial effusion, heart sounds are diminished (muffled heart sounds), and pulsus paradoxus (a fall in systolic pressure of 10mmHg or more on inspiration) appears. Constrictive pericarditis is characterized by the Kussmaul sign (paradoxical increase in jugular venous distension on inspiration) and a pericardial knock (a high-pitched heart sound just after S2).
In all patients diagnosed with acute rheumatic fever, echocardiography should be performed to comprehensively evaluate myocarditis, pericardial effusion, and valvular involvement. Echocardiography can detect carditis even without a clinical heart murmur and is essential for detecting 'subclinical carditis'. The 2015 AHA revised Jones criteria were changed so that echocardiographic findings alone can meet the major criterion of carditis.
When chronic rheumatic pericarditis is suspected, or when following patients with a history of rheumatic pericarditis for progression to constrictive pericarditis, cardiac CT (assessment of pericardial thickness and calcification) and cardiac MRI (pericardial inflammatory activity, pericardial thickening) are important screening tools. Chronic pericardial thickening (≥4mm) and hemodynamic abnormalities with respiratory variation are screening indicators for constrictive pericarditis.
The diagnosis of rheumatic myocarditis is made by combining clinical criteria (the major criterion of carditis in the revised Jones criteria) and test results. On the electrocardiogram, PR interval prolongation (first-degree atrioventricular block), ST-T wave abnormalities, and ectopic rhythms are observed. On echocardiography, reduced left ventricular ejection fraction (LVEF), wall motion abnormalities, and new valvular regurgitation are identified. Elevation of cardiac enzymes (troponin I/T, CK-MB) suggests myocardial necrosis. Cardiac MRI can accurately assess the extent and distribution of myocardial inflammation through patterns of myocardial edema (high signal on T2-weighted images), early pericardial enhancement (early gadolinium enhancement), and late gadolinium enhancement (LGE).
Rheumatic pericarditis is diagnosed by two or more of ① chest pain (pericarditic), ② pericardial friction rub, ③ electrocardiographic changes (widespread ST-segment elevation, PR-segment depression), and ④ pericardial effusion. Evidence of streptococcal infection (positive throat culture, elevated ASO) is essential to confirm a rheumatic cause. Constrictive pericarditis is confirmed by echocardiography (ventricular interdependence, Doppler findings), cardiac CT (measurement of pericardial thickness, calcification), cardiac MRI (pericardial enhancement), and cardiac catheterization (dip and plateau pattern of right and left ventricular pressures).
In the treatment of rheumatic myocarditis, GAS eradication (benzathine penicillin G or a 10-day course of oral penicillin V) is performed first, and as anti-inflammatory treatment, corticosteroids (prednisone 1–2mg/kg/day) are used in severe myocarditis. When heart failure is present, standard heart failure treatment including ACE inhibitors, diuretics, and beta-blockers (after cardiac function has stabilized) is given. In cardiogenic shock due to severe myocarditis, mechanical circulatory support devices such as cardiopulmonary support (extracorporeal membrane oxygenation, ECMO) may be needed.
In the treatment of rheumatic pericarditis, high-dose aspirin (75–100mg/kg/day) and colchicine (0.5mg twice daily, 3 months) are the first-line treatments. NSAIDs (ibuprofen, naproxen) can also be used. When cardiac tamponade due to pericardial effusion develops, immediate pericardiocentesis is needed. When it progresses to symptomatic chronic constrictive pericarditis, surgical pericardiectomy is the only definitive treatment. In pericardiectomy, total pericardiectomy is known to have fewer recurrences and a better prognosis than partial pericardiectomy.
The acute-phase prognosis of rheumatic myocarditis is closely related to the severity of myocarditis. In mild myocarditis, cardiac function mostly recovers completely, but in severe myocarditis there is a risk of death in the acute phase, and even in survivors, some progress to chronic cardiomyopathy (dilated cardiomyopathy). Rheumatic pericarditis has a low risk of death in the acute phase, but when it progresses to constrictive pericarditis, cardiac output decreases persistently and quality of life is seriously reduced. Symptomatic improvement is reported in 70–85% after pericardiectomy, and the 5-year postoperative survival rate is about 70–80%. When severe left ventricular dysfunction or myocardial fibrosis is present before surgery, the prognosis may be poor even after pericardiectomy.
The most important prevention of other rheumatic heart diseases is secondary prevention to prevent recurrence of rheumatic fever. Continuous administration of benzathine penicillin G (intramuscular injection every 3–4 weeks) prevents GAS reinfection and thus prevents repeated attacks of rheumatic myocarditis and pericarditis. For prevention of pericarditis recurrence, colchicine (recurrent pericarditis: 0.5mg twice daily, 6 months) is used as an evidence-based treatment. In patients with reduced left ventricular function after myocarditis, progression of heart failure should be detected early by regular echocardiographic follow-up and optimal drug therapy maintained. Restriction of physical activity is needed during acute myocarditis, and exercise is resumed gradually after cardiac function recovers.
Tanaka M, Hino K, Yajima T, et al. Rheumatic disease of the cardiac muscle. Cardiovascular Pathology. 2016;25(5):324-331. DOI: 10.1016/j.carpath.2016.05.002. PMID: 27423403.
Cunningham MW. Pathogenesis of group A streptococcal infections. Clinical Microbiology Reviews. 2000;13(3):470-511. DOI: 10.1128/CMR.13.3.470. PMID: 10885988.
Imazio M, Adler Y, Charron P. Recurrent pericarditis: modern approach in 2016. Current Cardiology Reports. 2016;18(5):50. DOI: 10.1007/s11886-016-0726-7. PMID: 27048272.
Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. European Heart Journal. 2015;36(42):2921-2964. DOI: 10.1093/eurheartj/ehv318. PMID: 26320112.
Gewitz MH, Baltimore RS, Tani LY, et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography. Circulation. 2015;131(20):1806-1818. DOI: 10.1161/CIR.0000000000000205. PMID: 25908771.
Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis. European Heart Journal. 2013;34(33):2636-2648. DOI: 10.1093/eurheartj/eht210. PMID: 23824828.
Steer AC, Carapetis JR. Prevention and treatment of rheumatic heart disease in the developing world. Nature Reviews Cardiology. 2009;6(11):689-698. DOI: 10.1038/nrcardio.2009.162. PMID: 19806148.
Bertog SC, Thambidorai SK, Parakh K, et al. Constrictive pericarditis: etiology and cause-specific survival after pericardiectomy. Journal of the American College of Cardiology. 2004;43(8):1445-1452. DOI: 10.1016/j.jacc.2003.11.048. PMID: 15093882.
Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112(13):2012-2016. DOI: 10.1161/CIRCULATIONAHA.105.542738. PMID: 16186437.
Carapetis JR, Beaton A, Cunningham MW, et al. Acute rheumatic fever and rheumatic heart disease. Nature Reviews Disease Primers. 2016;2:15084. DOI: 10.1038/nrdp.2015.84. PMID: 27188830.